Bifunctional HIV Inactivating Molecules via Conformational Triggering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV drugs, such as T20, require frequent and painful injections and are exorbitantly expensive, as they cannot inactivate HIV circulating in the blood before the virus attaches to target cells, necessitating high and costly maintenance of drug levels.
Innovation Solution
Development of bifunctional molecules containing a soluble CD4 domain and a gp41-binding peptide linked by a flexible linker, which can bind to HIV gp120 and gp41, triggering conformational changes to inhibit HIV entry into cells, thereby inactivating the virus before attachment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T20 peptide is used to block HIV entry by targeting gp41, then HIV fusion with host cell is inhibited, but the drug cannot inactivate HIV circulating in blood before virus attaches to target cell, requiring frequent high-dose injections
Solution Approach 1:
The patent applies preliminary action by designing a bifunctional molecule where the sCD4 domain first binds to gp120 on the viral surface, triggering conformational changes that expose gp41 epitopes before the virus can attach to the host cell. This preliminary binding event activates the second functional domain (CHR peptide) to subsequently bind exposed gp41, effectively inactivating the virus in circulation before attachment occurs, thereby reducing the need for frequent high-dose injections
Solution Approach 2:
The bifunctional molecule performs preliminary anti-action by pre-binding to gp120 and inducing conformational changes in the viral envelope that expose gp41 epitopes. This preliminary structural modification prevents the virus from properly attaching to host cells by altering the configuration of fusion-critical regions, thereby neutralizing the virus before it can initiate the fusion process
2Reliability
If T20 is administrated by injection twice a day at 90 mg/dose to maintain constant high concentration, then HIV entry is blocked, but painful injection-site reactions occur and cost exceeds $20,000/year/patient
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure from a single-domain CHR peptide (T20) to a bifunctional molecule comprising sCD4 domain linked to CHR peptide domain. This structural parameter change enables the molecule to bind gp120 first, triggering conformational changes that enhance subsequent gp41 binding affinity and duration, thereby achieving sustained HIV entry blocking at lower doses and reduced injection frequency
Solution Approach 2:
The invention employs composite materials by creating a bifunctional molecule that combines two distinct functional domains: the sCD4 domain (which binds gp120 and triggers conformational changes) and the CHR peptide domain (which binds exposed gp41). This composite structure leverages the synergistic effects of both domains to achieve enhanced and prolonged antiviral activity, reducing the need for frequent high-dose administrations and associated side effects
3Reliability
If single-function CHR peptides like T20 are used to bind gp41 NHR-trimer, then 6-HB formation is blocked, but the virus can still attach to target cell before drug interaction
Solution Approach 1:
The bifunctional molecule performs preliminary action by first binding to gp120 on the viral surface, which triggers conformational changes that expose gp41 epitopes. This preliminary binding event occurs before the virus can attach to the host cell, extending the time window for drug-virus interaction and enabling the second domain (CHR peptide) to subsequently bind the exposed gp41, thereby blocking 6-HB formation at an earlier stage
Solution Approach 2:
The sCD4 domain acts as an intermediary by first binding to gp120 and inducing conformational changes that expose gp41 epitopes. This intermediary action facilitates the subsequent binding of the CHR peptide domain to exposed gp41, creating a two-step mechanism that extends the interaction time and ensures effective blockade of viral entry even if the virus attempts to attach to the target cell
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These molecules can inactivate HIV circulating in the blood, reducing the need for frequent injections and lowering costs, while providing a novel mechanism of action effective against multi-drug resistant strains.
Implementation Method 1
bind to HIV gp120 and gp41, triggering conformational changes to inhibit HIV entry into cells
Implementation Method 2
a NHR-, CHR- or FP-binding peptide (CP) which can interact with the gp41 NHR, CHR or FP, respectively
Data Source
AI summary
Disclosed herein are bifunctional molecules which inactivate human immunodeficiency virus (HIV) even before the virus attacks the target cell and inhibits HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV. Further disclosed are methods for prophylaxis against HIV and treatment of HIV infection.